Johnson & Johnson (JNJ) says on track to become first healthcare company to exceed USD 100bln in annual revenue, with a clear line of sight to double-digit growth by the end of the decade
Importance
Level 1
- Executive says expects to elevate free cash flow generation to approximately USD 21bln in 2026.
#UNITED STATES#USD#EUR#JAPAN#JPY#UNITED KINGDOM#GBP#EUROPE#JOHNSON & JOHNSON#JNJ.US#FOREX#EQUITIES#METALS#EU SESSION#US SESSION#PHARMACEUTICALS#METALS & MINING#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#JNJ#DXY#US EQUITIES